FPI-2265 not checked
Fusion Pharmaceuticals Inc. · Ac225-PSMA I&T
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Small molecule capable of binding to the domain of PSMA radiolabeled with Ac225”In the company’s words, NCT05219500 on ClinicalTrials.gov
- Tested for
- Metastatic Castration-resistant Prostate Cancer (2 trials), Metastatic Castration Resistant Prostate Cancer
- Main trialPhase 2
- “The treatment regimen will consist of 4 doses of FPI-2265”In the company’s words, NCT05219500 on ClinicalTrials.gov
- Other names
- Ac225-PSMA I&T
Other drugs for Metastatic Castration-resistant Prostate Cancer
- ApalutamideJohnson & Johnson (Janssen) · Phase 3
- 64Cu-SAR-bisPSMAClarity Pharmaceuticals Ltd · Phase 3
- Abiraterone acetateJohnson & Johnson (Janssen) · Phase 3
- 68Ga-PSMA-11Telix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- EnzalutamidePfizer · Astellas · Phase 3
- MevrometostatPfizer · Phase 3
Coming up2
- 23 DecPhase 2 trial completes · ClinicalTrials.gov
- May 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 30 May 2025 | Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST). | |
| Phase 2Active, not recruiting | 23 Dec 2026 | FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) | |
| Phase 2Active, not recruiting | May 2027 | FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026